Abstract Submission :

Submit Abstract

Registration :

Register Now

Become a Sponsor/Exhibitor :

Become a Sponsor

Conference Organizing Committee :

View Committee

Register Now :

Register Now

Conference Program :

Brochure Download

SCIENTIFIC SESSIONS

  • Alzheimer's disease
  • Parkinson's disease
  • Dementia
  • Schizophrenia
  • Animal Models in Dementia
Read More

IMPORTANT DATES

Abstract Submission
June 29, 2018

Early Bird Registration
June 29, 2018

Register Now

Scientific Committee

Click on the image to view biography

Fred C. C. Peng

Neuroscientist, Taipei Veterans General Hospital, Taiwan

Dr. Peng is a behavioral neuroscientist with a wide range of interests in behavioral alterations caused by differing brain lesions: epilepsy, PD, stroke, SCA  He has published Does Alzheimer’s Disease Really Exist? (2008) and Alzheimer’s Disease: What Is It After All? (2012) and is working on setting the historical facts in time and place straight to change the fiction of Alzheimer’s Disease (AD) to the true eponym of Fischer’s Disease (FD) for plaques and tangles. In his latest publication, “Is Alzheimer’s Disease a Fiction?”., published in Clinical Researcj amd Trials, 2016, Vol 2(1)108-111, he concludes that Alzheimer’s Disease is a fiction.

He is currently affiliated with Taipei Veterans General Hospital in Taiwan at the Neurological Institute and the Department of Neurosurgery and conducts researches on controversies in dementia and language disorders.

Dr. Peng is listed in: (1) Who’s Who in the World (1991-); (2) Who’s Who in Science and Engineering, 4th Edition; (3) Men of Achievement, Seventeenth Edition; (4) Asia/Pacific Who’s Who in America (1990- ); (5) ific Who’s Who, 1997; (6) Dictionary of International Biography, 27th Edition; (7) Who’s Who in American Education, 6th Edition; (8) Asian/American Who’s Who, Vol. IV; (9) Great Minds of the 21st Century, 2004 Edition and 2007 Edition, The American Biographic Institute; (10) 2000 Outstanding Intellectuals of the 21st Century – 2011--, International Biographic Centre; (11) 500 Greatest Geniuses of the 21st Century, Priority Inclusion. The American Biographic Institute, (12) Man of the Year, 2011, The International Biographic Centre, Cambridge, (13) 2011 Man of the Year for Professional Excellence. The American Biographic Institute (14), The International Plato Award for Educational Achievement, Iconic Achievers, 2011. The International Biographic Centre, Cambridge. (15) Inclusion in the International Dictionary of Professionals, 2012, The American Biographic Institute, (16) 30th Pearl Anniversary Edition of Who’s Who in the World, November 2012.

Chang Yih-Hsin

Professor, National Yang Ming University, Taiwan

Dr. Chang holds a Ph.D. from Institue of Microbiology and Immunology from National Yang-Ming university. She is specialized in Diabetes Mellitus, Metabolic Syndrome, Microbiology/ Immunology and Medical Laboratory Sciences. She served different reputed positions in Universities. She holds many awards in her career. Recently in 2017 she was awarded the Annual academic award from Taiwan society of Laboratory science. She has more than 50 publications in the reputed scientific journals.

Joanna B Strosznajder

Neuroscientist, MMRC Polish Academy of Sciences, Poland

Professor Joanna B Strosznajder obtained MD degree and the specialization in neurology in Warsaw Medical Academy (now Medical University of Warsaw) Ph.D. in biochemistry in Institute of Immunology,Polish Academy of Sciences in Wroclaw.Then she was recruited to the Biochemistry Department in Institute of Neuropathology Polish Academy of Sciences (PAS) in Warsaw and after her Ph.D. she obtained Alexander von Humboldt fellowship in Department of Biochemistry University of Cologne, Germany where she spend a very successful 2 years. Prof. JB Strosznajder is internationally recognized neuro scientist in the field of brain lipids,oxidative/nitrosative stress and signaling pathways in relation to cancer, brain ischemia, aging and neurodegenerative disease including Alzheimer’s and Parkinson’s Diseases(AD/PD). Prof. JB Strosznajderwas the head of Department of Cellular Signalling and the Head of Scientific Council in Medical Research Centre PAS.She training large number of students, graduates and post docs. Moreover, she organized many national and international meetings and conferences. Prof. J Strosznajder published close 200 original articles in highly recognized journals.She was awarded by Alexander vonHumboldtand MeyerhoffFoundations and few times by PAS awards the last in 2012. Now Prof. JBStrosznajderwith her Ph.D. students realize the study on the role of bioactive lipids and NAD+ dependent enzymes(PARPsand Sirts)in AD/PD.

About Event


We are pleased to welcome the scientific fraternity across the world to join Global Alzheimer’s and Dementia Conference to be held during August 27-29, 2018 in Rome, Italy.

Our scientific program, presented over the course of three days will have the productive sessions of keynote presentations, oral sessions, young research forum, symposia, poster presentation, workshops, exhibitions, roundtables and variable formats. This conference gathers Doctors, Scientists, Professors, and other Medical and Clinical Researchers both from academic and business organizations globally.

Join us to redefine and explore new research, to provide a credible source to barter ideas for scientific studies besides transforming the true outcomes of a distinct scientific discovery and grab the attention for rare emerging technologies.

Importance and Scope

Global Alzheimer’s and Dementia Conference aims to showcase the scientific developments that are already resulting in measurable benefits for patients suffering with Alzheimers and Dementia. Our conference is based on the theme “Changing the perception and enhancing new strategies to fight Dementia”.

Conference Objectives

  • To facilitate opportunities for networking, collaboration and exchange of ideas with internationally renowned researchers fighting against Alzheimers and Dementia.
  • To identify research and practice based innovations in optimizing diagnosis for Alzheimer.
  • To debate gaps and priorities for sustainable development and solutions to fight Dementia research.

 

Why to attend?

Dementia and Alzheimers research has provided a deeper understanding of how much Alzheimer’s affects the brain, in the last three decades. Today, Scientists and researchers across the world are continuing to look for more effective treatments and cure, to prevent Alzheimer’s and improve brain health. So, Global Alzheimer’s and Dementia Conference provides a platform to the researchers to distribute information, conduct presentations and meet with current and potential scientists across the globe who are working mutually towards Dementia Research.  Make a splash with new researches and its developments in this 2-day event at Dementia and Alzheimers 2018 conference. World-renowned speakers, recent techniques, developments and newest updates in Dementia research and treatment are major parts of this conference.

 

Young Researchers Opportunity

  • Establishing their academic and professional relationships.
  • Improving their morale and confidence of presenting research in an international platform.
  • Interacting with expertise in their respective departments.
  • Clearing your inhibitions of adjusting to the foreign environment.
  • Providing a holistic experience of academic tourism.

Target Audience

  • Academicians
  • Medical Colleges
  • Research faculty
  • Students
  • Oncologists
  • Pathologists
  • Cancer & Oncology Societies Professionals
  • Diagnostic laboratory professionals          
  • Presidents & Vice Presidents
  • Directors/Managers/CEO’s
  • Bio-Medical Company professionals
  • Industry Professionals
  • Corporate Cancer Research Professional
  • Pharmacists Business Entrepreneurs
  • Medical Devices Companies
  • Biotechnology Companies
  • Marketing, Advertising and Promotion Agency Executives.

Scientific Session


Alzheimer's disease

Alzheimer's is a type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks. Alzheimer's disease accounts for 60 to 80 percent of dementia cases.

Parkinson's disease

Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson's disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Dementia

Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. It is caused by physical changes in the brain.

Alzheimer's disease is the most common cause of a progressive dementia in older adults, but there are a number of causes of dementia. Depending on the cause, some dementia symptoms can be reversed.

Dementia symptoms vary depending on the cause, but common signs and symptoms include  Memory loss, cognitive changes, Psychological changes, Difficulty with coordination and motor functions

Diagnosis of dementia . Diagnosing dementia and determining what type it is can be challenging. A diagnosis of dementia requires that at least two core mental functions be impaired enough to interfere with daily living. They are memory, language skills, ability to focus and pay attention, ability to reason, solve problem and visual perception. No single test can diagnose dementia, so doctors are likely to run a number of tests that can help pinpoint the problem. Some of the tests include Cognitive and neuropsychological tests, Brain scans and Psychiatric evaluation.

Schizophrenia

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. People with schizophrenia may seem like they have lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling.

Because the causes of schizophrenia are still unknown, treatments focus on eliminating the symptoms of the disease. Some of the common symptoms are Hallucinations, Movement disorders (agitated body movements), Reduced speaking

Animal Models in Dementia

Many clinical studies focus on finding better ways to accurately diagnose Alzheimer's disease, particularly in the early stages. These studies will hopefully lead to a trusted and easy-to-apply method that enables physicians to diagnose persons at risk for the disease even before symptoms appear and begin treatment.

Diagnostic studies are vital to the advancement of Alzheimer's research because they identify which individuals to treat and provide doctors with a way to track whether a treatment is working. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Drug Development in Dementia

Many clinical studies focus on finding better ways to accurately diagnose Alzheimer's disease, particularly in the early stages. These studies will hopefully lead to a trusted and easy-to-apply method that enables physicians to diagnose persons at risk for the disease even before symptoms appear and begin treatment.

Diagnostic studies are vital to the advancement of Alzheimer's research because they identify which individuals to treat and provide doctors with a way to track whether a treatment is working. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammation and neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and ongoing promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Neurodegenerative Diseases

Neurodegenerative diseases affect millions of people worldwide, and Alzheimer’s disease and Parkinson’s disease are the most common types. More than five million Americans are living with Alzheimer’s disease, and at least 500,000 Americans live with Parkinson's disease, although some estimates are much higher.

Neurodegenerative diseases occur when nerve cells in the brain or peripheral nervous system lose function over time and ultimately die. Although treatments may help relieve some of the physical or mental symptoms associated with neurodegenerative diseases, there is currently no cure or way to slow disease progression.

The risk of being affected by a neurodegenerative disease increases dramatically with age. Population-wide health improvements have increased lifespan, which along with a larger generation of aging Americans means more people may be affected by neurodegenerative diseases in coming decades. This creates a critical need to improve our understanding of what causes neurodegenerative diseases and develop new approaches for treatment and prevention.

Depression and Anxiety Disorders

Depression and anxiety disorders are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. But each disorder has its own causes and its own emotional and behavioural symptoms

There are different types of depressive disorders, and while there are many similarities among them, each depressive disorder has its own unique set of symptoms. A person may lose interest in work, hobbies and doing things he or she normally enjoys. Some people may lack energy, have difficulty sleeping or sleep more than usual, while some people feel anxious or irritable and find it hard to concentrate.

 

 

Scientific Sessions

Abstract Submission : June 29, 2018

Early Bird Registration : June 29, 2018

  • Alzheimer's disease
  • Parkinson's disease
  • Dementia
  • Schizophrenia
  • Animal Models in Dementia
  • Drug Development in Dementia
  • Neurodegenerative Diseases
  • Depression and anxiety disorders
  • Epilepsy
  • Migraine
  • Motor Neurone diseases
  • Neurodegenertaion
  • CNS Disorders

Registration Categories

Abstract Submission : June 29, 2018

Early Bird Registration : June 29, 2018

Awards

GADC (Global Alzheimer’s & Dementia Conference) anticipates being able to provide funding to assist some attendees coming from Lower and Middle Income Countries to present their science at the summit.  Participants desiring to be considered for one of these awards need to specify their interest after their submission of the required abstract. Selected participants will receive a sum of $250 to $1,000 (USD) scholarship under the 3 categories.

1.     Outstanding Submitted Abstract of the GADC.

2.     Best Research of the conference as evaluated by the Scientific Committee.

3.     Young Researcher Award under YRF category to encourage budding scientists/ researcher.

Decisions will be made based on evaluation of the submitted abstract by the scientific committee and amount of funds available.

We want you to grab this opportunity and participate in the conference.

Conference Venue

Hotel Mercure Roma West,  ROME, Italy

Need Help ? Write to Us